Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Jutta Heim

28 August 2019

From 2009 to 2013 Professor Jutta Heim was the Chief Scientific Officer of Evolva SA with responsibility for all Synthetic Biology and metabolic engineering work for the production of new or known natural products. Before that position, Dr Heim was Chief Scientific Officer of Basilea Pharmaceutica AG, a Swiss biopharmaceutical company, where she was in charge of all anti-infective, dermatology and oncology discovery activities. Prior to joining Basilea Pharmaceutica, Dr Heim worked for 22 years in Switzerland and the United States for Ciba-Geigy/Novartis, where she was involved in the successful development and launch of biopharmaceuticalanti-thrombotic and fibrinolytic products, initiated a molecular genetics department in oncology and became Novartis’ Senior Scientific Expert in Molecular Biology and a member of the Research Management Board. She is currently the Chair of the GARDP Scientific Advisory Committee, and holds non-executive director positions in several boards. She is titular Professor of Biotechnology at the University of Basel, Switzerland.